Role of integrin-linked kinase in vascular smooth muscle cells: Regulation by statins and angiotensin II
- Klinik fuer Innere Medizin III - Kardiologie, Angiologie, Internistische Intensivmedizin, Universitaetskliniken des Saarlandes, 66421 Homburg (Germany)
- Klinik fuer Innere Medizin II, Universitaetsklinikum Bonn, 53105 Bonn (Germany)
Our goal was to characterize the role of integrin-linked kinase (ILK) in vascular smooth muscle cells (VSMC), which play a crucial role in atherogenesis. Transfection of VSMC with wild-type and dominant-negative ILK cDNA constructs revealed that ILK mediates migration and proliferation of VSMC but has no effect on VSMC survival. The pro-atherogenic mediator angiotensin II increases ILK protein expression and kinase activity while statin treatment down-regulates ILK in VSMC. Functionally, ILK is necessary for angiotensin II-mediated VSMC migration and proliferation. In VSMC transduced with dominant-negative ILK, statins mediate an additive inhibition of VSMC migration and proliferation, while transfection with wild-type ILK is sufficient to overcome the inhibitory effects of statin treatment on VSMC migration and proliferation. In vivo, ILK is expressed in VSMC of aortic sections from wild-type mice where it is down-regulated following statin treatment and up-regulated following induction of atherosclerosis in apoE-/- mice. These data identify ILK as a novel target in VSMC for anti-atherosclerotic therapy.
- OSTI ID:
- 20854536
- Journal Information:
- Biochemical and Biophysical Research Communications, Vol. 349, Issue 3; Other Information: DOI: 10.1016/j.bbrc.2006.07.217; PII: S0006-291X(06)01755-4; Copyright (c) 2006 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0006-291X
- Country of Publication:
- United States
- Language:
- English
Similar Records
Role of integrin-linked kinase for functional capacity of endothelial progenitor cells in patients with stable coronary artery disease
Piperlongumine inhibits atherosclerotic plaque formation and vascular smooth muscle cell proliferation by suppressing PDGF receptor signaling